ArticleFoods (Basel, Switzerland)2026
Honey Lemon Alleviates Alcoholic Liver Disease via Multi-Target Synergistic Mechanisms: An Integrated Study of Network Pharmacology, Molecular Docking, and Animal Experiments.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Honey lemon (H&L) is a traditional beverage known for its potential liver-protective effects, but its mechanisms against alcoholic liver disease (ALD) remain poorly understood. This study aimed to investigate the hepatoprotective properties of H&L and explore its multi-target mechanisms in alleviating ALD. Using network pharmacology and molecular docking, we identified 26 bioactive compounds in H&L and 335 potential targets associated with ALD. Pathway enrichment analysis revealed that H&L might exert its influence by regulating inflammation, oxidative stress and ethanol metabolism. Molecular docking further demonstrated strong binding interactions between key flavonoids (hesperidin, diosmin, and eriocitrin) and crucial targets, such as AKT1, SRC, STAT3, as well as ethanol-metabolizing enzymes like ADH, ALDH, and CYP2E1. In vivo experiments suggested that H&L alleviated liver injury and significantly improved selected indicators related to ethanol metabolism, oxidative stress, and inflammatory response. For several variables, including ALT/AST, ALDH, IL-6, and hepatic ethanol content, improvement trends were observed, although not all differences reached statistical significance. Overall, the results suggest that the protective effect of H&L against ALD may be associated with a multi-component, multi-target, and multi-pathway mode of action, supporting its potential for further investigation as a functional food candidate.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.